<DOC>
	<DOCNO>NCT00688103</DOCNO>
	<brief_summary>Multi-center , parallel-group , randomize , open control study . All patient select two treatment group . 1 . Etanercept alone treatment group ( 25mg , twice/week , s.c. ) 2 . Etanercept combine MTX group ( 25mg , twice/week , s.c.+MTX 6-8mg/week )</brief_summary>
	<brief_title>Efficacy Safety Etanercept Active RA Despite Methotrexate Therapy Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients least 18 year age fulfil 1987 revise classification criterion RA American College Rheumatology ( ACR ) meet guideline proper use ETN Japan ( least 6 tender joint 6 swollen joint either serum Creactive protein 2 mg/dl ESR le 28 mm 1 hour , adequate safety profile ) ACR functional class IIII receive MTX 6 mg/week minimum 3 month stable dose least 4 week time study enrollment Patients require concurrent use prednisone ( PSL ) &gt; 10 mg/day , equivalent , exclude study entry start dose increment PSL equivalent within 3 month study enrollment experience antirheumatic therapy except MTX PSL equivalents previous treatment ETN biological treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>